stockrowArcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
- Revenue
- +45.1%
- EPS
- +12.0%
- Free cash flow
- +1,171.9%
- Total debt
- +0.83%
Quarter to September 2026, against a year earlier
Follow ARQT
Alert me
Arcutis Biotherapeutics, Inc. (ARQT) EV/EBITDA
As of 6 November 2026, Arcutis Biotherapeutics, Inc. (ARQT) trades at a EV/EBITDA of 86.8×. Over the past ten years it has ranged from 0.0× (March 2026) to 847× (June 2026); the current reading is higher than 92% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 8.4×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 89.9× | (2.93%) |
| Jun 2026 | 92.6× | (87.23%) |
| Mar 2026 | 725× | — |
| Dec 2025 | 0.0× | — |
| 13 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| LEGN Legend Biotech Corporation Sponsored ADR compare | n/m |
| DFTX Definium Therapeutics, Inc. compare | n/m |
| TNGX Tango Therapeutics, Inc. compare | n/m |
| EWTX Edgewise Therapeutics, Inc. compare | n/m |
| DNTH Dianthus Therapeutics, Inc. compare | n/m |
| ABCL AbCellera Biologics Inc. compare | n/m |
| IOVA Iovance Biotherapeutics, Inc. compare | n/m |
| RLAY Relay Therapeutics, Inc. compare | n/m |
| ARQT Arcutis Biotherapeutics, Inc. | 92.8× |
| Biotechnology industry median | 0.7× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on ARQT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement